Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Shares Sold by Bourgeon Capital Management LLC
Bourgeon Capital Management LLC reduced its stake in Sangamo Therapeutics, Inc. (NASDAQ:SGMO) by 64.3% during the second quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 11,500 shares of the biopharmaceutical company’s stock after selling 20,700 shares during the period. Bourgeon Capital Management LLC’s holdings in Sangamo Therapeutics were worth $101,000 as of its most recent SEC filing.
Several other institutional investors also recently added to or reduced their stakes in SGMO. Aperio Group LLC bought a new position in Sangamo Therapeutics during the second quarter valued at approximately $108,000. Fox Run Management L.L.C. bought a new position in Sangamo Therapeutics during the second quarter valued at approximately $126,000. Russell Investments Group Ltd. bought a new position in Sangamo Therapeutics during the second quarter valued at approximately $203,000. Gilder Gagnon Howe & Co. LLC bought a new position in Sangamo Therapeutics during the first quarter valued at approximately $154,000. Finally, Bank of America Corp DE increased its position in Sangamo Therapeutics by 49.9% in the first quarter. Bank of America Corp DE now owns 32,625 shares of the biopharmaceutical company’s stock valued at $169,000 after buying an additional 10,861 shares during the period. 58.25% of the stock is currently owned by hedge funds and other institutional investors.
Shares of Sangamo Therapeutics, Inc. (SGMO) opened at 10.25 on Friday. The company has a 50-day moving average of $9.08 and a 200 day moving average of $6.17. Sangamo Therapeutics, Inc. has a 12 month low of $2.65 and a 12 month high of $10.50. The company’s market cap is $737.37 million.
Sangamo Therapeutics (NASDAQ:SGMO) last posted its quarterly earnings results on Wednesday, August 9th. The biopharmaceutical company reported ($0.17) EPS for the quarter, topping the consensus estimate of ($0.23) by $0.06. Sangamo Therapeutics had a negative return on equity of 38.49% and a negative net margin of 246.39%. The business had revenue of $8.30 million for the quarter, compared to analyst estimates of $5.82 million. During the same quarter in the previous year, the firm earned ($0.38) EPS. The company’s quarterly revenue was up 124.3% compared to the same quarter last year. On average, analysts anticipate that Sangamo Therapeutics, Inc. will post ($0.98) earnings per share for the current year.
Several equities research analysts recently weighed in on the stock. ValuEngine upgraded shares of Sangamo Therapeutics from a “sell” rating to a “hold” rating in a research report on Friday. Piper Jaffray Companies set a $8.00 price target on shares of Sangamo Therapeutics and gave the stock a “hold” rating in a research report on Thursday. BidaskClub cut shares of Sangamo Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, August 5th. Wedbush restated a “neutral” rating and issued a $4.00 price target (down previously from $6.00) on shares of Sangamo Therapeutics in a research report on Tuesday, May 16th. Finally, Zacks Investment Research upgraded shares of Sangamo Therapeutics from a “sell” rating to a “hold” rating in a research report on Tuesday, May 16th. One equities research analyst has rated the stock with a sell rating, four have assigned a hold rating and two have issued a buy rating to the stock. The stock presently has a consensus rating of “Hold” and a consensus price target of $9.67.
In related news, VP Curt A. Herberts III sold 15,000 shares of the firm’s stock in a transaction dated Friday, July 14th. The stock was sold at an average price of $10.00, for a total transaction of $150,000.00. Following the completion of the sale, the vice president now directly owns 35,517 shares of the company’s stock, valued at approximately $355,170. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 8.10% of the stock is currently owned by company insiders.
Sangamo Therapeutics Company Profile
Sangamo Therapeutics, Inc, formerly Sangamo BioSciences, Inc, is a clinical-stage biotechnology company. The Company is focused on translating science into genomic therapies that transform patients’ lives using the Company’s platform technologies in genome editing, gene therapy, gene regulation and cell therapy.
Want to see what other hedge funds are holding SGMO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Sangamo Therapeutics, Inc. (NASDAQ:SGMO).
Receive News & Ratings for Sangamo Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sangamo Therapeutics Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.